AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Fmr LLC

Fmr LLC boosted its stake in AstraZeneca PLC (NASDAQ:AZN) by 1.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,117,447 shares of the company’s stock after buying an additional 258,477 shares during the period. Fmr LLC’s holdings in AstraZeneca were worth $1,801,080,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Stratos Wealth Advisors LLC increased its holdings in shares of AstraZeneca by 2.0% during the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after purchasing an additional 133 shares during the period. Bruce G. Allen Investments LLC grew its holdings in AstraZeneca by 19.1% during the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock worth $67,000 after acquiring an additional 138 shares during the period. Carnegie Investment Counsel boosted its position in shares of AstraZeneca by 0.8% in the 2nd quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock valued at $1,347,000 after purchasing an additional 138 shares during the period. Crumly & Associates Inc. boosted its holdings in shares of AstraZeneca by 2.2% in the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after buying an additional 143 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its position in AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after purchasing an additional 146 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Trading Down 0.1 %

AstraZeneca stock opened at $66.36 on Wednesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The business’s 50-day simple moving average is $72.94 and its 200-day simple moving average is $77.65. The firm has a market capitalization of $205.76 billion, a PE ratio of 31.75, a PEG ratio of 1.22 and a beta of 0.47. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period in the previous year, the company posted $0.87 earnings per share. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. Equities research analysts forecast that AstraZeneca PLC will post 4.1 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on AZN shares. TD Cowen lifted their target price on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Finally, UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.